Effect of Switching from Telmisartan, Valsartan, Olmesartan, or Losartan to Candesartan on Morning Hypertension

• Published in: Clinical and Experimental Hypertension Vol. 34; no. 2; pp. 86 - 91
• Main Authors: Hasegawa, Hiroshi, Takano, Hiroyuki, Kameda, Yoshihito, Kubota, Akihiko, Kobayashi, Yoshio, Komuro, Issei
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01.04.2012; Taylor & Francis; Informa UK Limited
• Subjects: Aged; angiotensin II receptor blocker; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Antihypertensive Agents; Antihypertensive Agents - therapeutic use; Asian Continental Ancestry Group; Asian People; Benzimidazoles; Benzimidazoles - therapeutic use; Benzoates; Benzoates - therapeutic use; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; candesartan; Circadian Rhythm; clinical trial; Female; Humans; Hypertension; Hypertension - drug therapy; Hypertension - physiopathology; Imidazoles; Imidazoles - therapeutic use; Japan; Losartan; Losartan - therapeutic use; Male; Middle Aged; Prospective Studies; Telmisartan; Tetrazoles; Tetrazoles - therapeutic use; Valine; Valine - analogs & derivatives; Valine - therapeutic use; Valsartan; Japan
• ISSN: 1064-1963; 1525-6006; 1525-6006
• DOI: 10.3109/10641963.2011.628729

The Candesartan Cooperative Research of Therapy Design for Early Morning Hypertension in CHIBA was designed to investigate whether switching from angiotensin II receptor blockers (ARBs) except candesartan to candesartan might be effective in Japanese patients with morning hypertension. Seventy-eight mild to moderate hypertensive patients, who were treated with the standard doses of ARBs except candesartan (losartan, 50 mg; valsartan, 80 mg; telmisartan, 40 mg; or olmesartan, 20 mg), were entered into 12-week treatment period with candesartan 8 mg according to a multicenter, open-label design. Morning and office blood pressures (BPs) were significantly reduced (morning, −10.1 ± 10.5/−4.5 ± 8.4 mm Hg; office, −13.1 ± 17.3/−6.2 ± 11.3 mm Hg) after medication change. Target BPs (morning BPs ≤ 135/85 mm Hg and office BPs ≤ 140/90 mm Hg) achievement rates were 42.9% in the morning and 64.3% at office. No adverse events were recognized in all patients. Candesartan treatment significantly reduced the morning and office BPs compared with other ARBs in Japanese patients with morning hypertension.